Everest Expands Ophthalmology Portfolio in China

Everest Medicines acquires rights to presbyopia eye drop

1

Everest Medicines has signed an asset purchase agreement with Corxel Pharmaceuticals to develop LNZ100 for presbyopia in Greater China.
2

LNZ100, a 1.44 percent aceclidine solution, aims to improve near vision by inducing pupil constriction without affecting distance vision.
3

The therapy was approved in the US in July 2025 and is expected to receive approval in China by the first quarter of 2027.
4

A Phase 3 trial involving 300 participants demonstrated LNZ100's efficacy, showing significant improvements in near vision.
5

Presbyopia affects nearly 100% of individuals by age 52 in China, with current treatment options being limited and often inconvenient.

1